Open Access BASE2022

Examining the unit costs of COVID-19 vaccine delivery in Kenya

Abstract

Background Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is implementing a phased strategy to vaccinate the Kenyan population, initially targeting populations at high risk of severe disease and infection. We estimated the financial and economic unit costs of procuring and delivering the COVID-19 vaccine in Kenya across various vaccination strategies. Methods We used an activity-based costing approach to estimate the incremental costs of COVID-19 vaccine delivery, from a health systems perspective. Document reviews and key informant interviews(n = 12) were done to inform the activities, assumptions and the resources required. Unit prices were derived from document reviews or from market prices. Both financial and economic vaccine procurement costs per person vaccinated with 2-doses, and the vaccine delivery costs per person vaccinated with 2-doses were estimated and reported in 2021USD. Results The financial costs of vaccine procurement per person vaccinated with 2-doses ranged from 2.89-13.09 US dollars in the 30% and 100% coverage levels respectively, however, the economic cost was 17.34 US dollars across all strategies. Financial vaccine delivery costs per person vaccinated with 2-doses, ranged from 4.28-3.29 US dollars in the 30% and 100% coverage strategies: While the economic delivery costs were two to three times higher than the financial costs. The total procurement and delivery costs per person vaccinated with 2-doses ranged from 7.34-16.47 US dollars for the financial costs and 29.7-24.68 US dollars for the economic costs for the 30% and 100% coverage respectively. With the exception of procurement costs, the main cost driver of financial and economic delivery costs was supply chain costs (47–59%) and advocacy, communication and social mobilization (29–35%) respectively. Conclusion This analysis presents cost estimates that can be used to inform local policy and may further inform parameters used in cost-effectiveness models. The results could potentially be ...

Sprachen

Englisch

Verlag

BioMed Central

DOI

10.1186/s12913-022-07864-z

Problem melden

Wenn Sie Probleme mit dem Zugriff auf einen gefundenen Titel haben, können Sie sich über dieses Formular gern an uns wenden. Schreiben Sie uns hierüber auch gern, wenn Ihnen Fehler in der Titelanzeige aufgefallen sind.